PD-L1 is highly expressed in Enzalutamide resistant prostate cancer

Efficacy of Enzalutamide (ENZ) in castration resistant prostate cancer (CRPC) patients is short-lived. Immunotherapy like T cell checkpoint blockade may improve patient survival. However, when and where checkpoint molecules are expressed in CRPC and whether immune evasion is a mechanism of ENZ resis...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Bishop, Jennifer L., Sio, Alexander, Angeles, Arkhjamil, Roberts, Morgan E., Azad, Arun A., Chi, Kim N., Zoubeidi, Amina
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2014
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4381591/
https://ncbi.nlm.nih.gov/pubmed/25428917
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados